falsefalse

Updates in Treatment Approaches for Ovarian and Endometrial Cancers - Episode 6

Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

, , , ,

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Frontline Maintenance Therapy in Ovarian Cancer
    EP. 2: Ovarian Cancer: Deciding Between Treatment Options
    EP. 3: Unmet Needs in the Maintenance Setting in Ovarian Cancer
    EP. 4: Recent Data on PARP Inhibitors as First-Line Maintenance in Ovarian Cancer
    EP. 5: Efficacy of Subsequent Therapies in Advanced Ovarian Cancer
    Now Viewing
    EP. 6: Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer
    EP. 7: Ongoing Trials on Maintenance Therapy in Recurrent Ovarian Cancer
    EP. 8: MIRASOL Trial: Mirvetuximab in Platinum-Resistant Ovarian Cancer
    EP. 9: Recently Presented Data on Endometrial Cancer
    EP. 10: NRG-GY018 and RUBY Trials in Endometrial Cancer
    EP. 11: The PHAEDRA Study and Clinical Trial Landscape in Endometrial Cancer
    EP. 12: KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer
    EP. 13: Ongoing Trials in Endometrial Cancer
    EP. 14: Future Outlook for Treatment of Endometrial Cancer

    Related Content:

    Updates in Treatment Approaches for Ovarian and Endometrial CancersUCLA Health Jonsson Comprehensive Cancer CenterDana-Farber Cancer InstituteNYU Langone's Perlmutter Cancer CenterWashington University School of Medicine in St. Louis The University of Texas MD Anderson Cancer CenterOvarian CancerGynecologic OncologyOncLive Peer Exchange®
    Five Under 5: Top Oncology Videos for the Week of 5/18
    Dr Wang on Key Findings From a Study of the Tumor Microenvironment in ccRCC
    Dr Lantsman on Future Directions for Evaluating Dostarlimab/Chemo in Endometrial Cancer
    x